middle.news
Alterity Therapeutics Advances ATH434 with Strong Phase 2 MSA Trial and A$27M Capital Boost
5:03am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Advances ATH434 with Strong Phase 2 MSA Trial and A$27M Capital Boost
5:03am on Monday 2nd of June, 2025 AEST
Key Points
Positive topline results from ATH434-201 Phase 2 double-blind trial in MSA
Completion of ATH434-202 open-label trial in advanced MSA with data expected mid-2025
Cash balance of A$17.96M at quarter end, plus A$27.1M raised post-quarter
Operating cash outflows of A$0.73M for Q3 FY25
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE